Tempus AI, Inc. (NASDAQ:TEM - Get Free Report)'s stock price was up 11.7% during mid-day trading on Wednesday . The stock traded as high as $35.66 and last traded at $35.54. Approximately 1,205,110 shares changed hands during mid-day trading, a decline of 67% from the average daily volume of 3,677,894 shares. The stock had previously closed at $31.83.
Wall Street Analyst Weigh In
Several equities research analysts have recently commented on TEM shares. Bank of America upped their price target on shares of Tempus AI from $52.00 to $54.00 and gave the company a "neutral" rating in a research report on Friday, December 13th. Needham & Company LLC reiterated a "buy" rating and issued a $56.00 price target on shares of Tempus AI in a research report on Tuesday. Guggenheim started coverage on Tempus AI in a report on Monday, December 9th. They set a "buy" rating and a $74.00 price target for the company. Piper Sandler reaffirmed a "neutral" rating and issued a $70.00 price objective (up previously from $40.00) on shares of Tempus AI in a research note on Tuesday, November 12th. Finally, Loop Capital cut their price objective on Tempus AI from $57.00 to $52.00 and set a "buy" rating for the company in a research note on Tuesday. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $56.36.
Get Our Latest Report on TEM
Tempus AI Trading Up 1.2 %
The business's 50-day moving average price is $46.80 and its 200-day moving average price is $47.09. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55.
Insider Transactions at Tempus AI
In related news, CEO Eric P. Lefkofsky sold 187,655 shares of the stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $37.54, for a total value of $7,044,568.70. Following the transaction, the chief executive officer now owns 9,557,283 shares in the company, valued at approximately $358,780,403.82. This represents a 1.93 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Bradley A. Keywell sold 395,800 shares of the firm's stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $42.95, for a total transaction of $16,999,610.00. Following the transaction, the insider now directly owns 16,164,449 shares of the company's stock, valued at $694,263,084.55. This represents a 2.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 865,041 shares of company stock valued at $35,917,673 in the last quarter.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in the business. SG Americas Securities LLC acquired a new stake in Tempus AI during the 4th quarter worth about $372,000. Dakota Wealth Management raised its position in Tempus AI by 189.7% during the fourth quarter. Dakota Wealth Management now owns 60,668 shares of the company's stock valued at $2,048,000 after acquiring an additional 39,724 shares in the last quarter. Avanza Fonder AB acquired a new position in Tempus AI in the fourth quarter valued at approximately $1,197,000. Bouvel Investment Partners LLC purchased a new stake in Tempus AI in the 4th quarter worth approximately $1,029,000. Finally, FNY Investment Advisers LLC acquired a new stake in shares of Tempus AI during the 4th quarter worth approximately $67,000. Hedge funds and other institutional investors own 24.22% of the company's stock.
About Tempus AI
(
Get Free Report)
Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
Further Reading
Before you consider Tempus AI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tempus AI wasn't on the list.
While Tempus AI currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
